Encompass Health announces date of 2024 first quarter earnings call
Encompass Health announces date of 2024 first quarter earnings call
PR Newswire
BIRMINGHAM, Ala., April 10, 2024
BIRMINGHAM, Ala., April 10, 2024 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will report results for its first quarter ended March 31, 2024, after the market closes Wednesday, April 24, 2024. The Company will host an investor conference call at 10 a.m. ET on April 25, 2024, to discuss its results.
The conference call may be accessed by dialing 800-579-2543 and giving the conference ID EHCQ124. International callers should dial 785-424-1699 and give the same conference ID. Please call approximately 10 minutes before the start of the call to ensure you are connected.
A live webcast of the conference call and an online replay of the conference call can be found on the Company's investor website at https://investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of rehabilitation hospitals in the United States. With a national footprint that includes 160 hospitals in 37 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies and Modern Healthcare's Best Places to Work in Healthcare. For more information, visit encompasshealth.com, or follow us on our newsroom, Twitter, Instagram and Facebook.
Media contact:
Kennedi Spurling | 205-970-5912
kennedi.spurling@encompasshealth.com
Investor Relations contact:
Mark Miller | 205-970-5860
mark.miller@encompasshealth.com
SOURCE Encompass Health Corp.
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast